Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Uridine-5'-diphosphate-4-deoxy-4-fluoro-alpha-D-galactose is a synthetic nucleotide sugar derivative belonging to the class of pyrimidine nucleotide sugars, characterized by a pyrimidine nucleotide (uridine) bound to a saccharide derivative through the terminal phosphate group. It is an experimental small molecule that serves as an analogue and substrate for glycosyltransferases in biochemical studies, particularly those involving glycosylation processes. The compound features selective fluorination and deoxygenation at the 4-position of the galactose moiety, which can alter its interaction with enzymes such as UDP-galactose 4’-epimerase. It has been used as a substrate analogue in structural biology research to study enzyme mechanisms and substrate binding[1][3][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on uridine-5'-diphosphate-4-deoxy-4-fluoro-alpha-D-galactose.